Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DDR1 monoclonal antibody PRTH-101

A humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against discoid domain receptor type 1 (DDR1), with potential immunomodulating and antineoplastic activities. Upon administration, anti-DDR1 monoclonal antibody PRTH-101 specifically targets, binds to and blocks DDR1, a protein expressed on tumor cells that binds collagen to make a minimally permeable physical barrier that blocks immune cells in the tumor microenvironment (TME) from interacting with and attacking the tumor. By blocking DDR1, PRTH-101 causes the collagen fibers lose alignment and loosen. This creates gaps in the tumor barrier, thereby allowing cytotoxic T-cells to enter and attack the tumor.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:PRTH 101
PRTH-101
PRTH101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search